Dong-A ST Co., Ltd. (KRX:170900)
36,300
-2,050 (-5.35%)
Last updated: Jun 8, 2026, 1:41 PM KST
Dong-A ST Revenue
Dong-A ST had revenue of 203.58B KRW in the quarter ending March 31, 2026, with 11.80% growth. This brings the company's revenue in the last twelve months to 830.27B, up 14.58% year-over-year. In the year 2025, Dong-A ST had annual revenue of 808.78B with 15.89% growth.
Revenue (ttm)
830.27B
Revenue Growth
+14.58%
P/S Ratio
0.44
Revenue / Employee
494.50M
Employees
1,679
Market Cap
368.63B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 808.78B | 110.91B | 15.89% |
| Dec 31, 2024 | 697.87B | 33.89B | 5.10% |
| Dec 31, 2023 | 663.98B | 28.59B | 4.50% |
| Dec 31, 2022 | 635.39B | 42.16B | 7.11% |
| Dec 31, 2021 | 593.23B | 6.50B | 1.11% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| JW Holdings | 973.26B |
| Huons Global | 845.30B |
| Huons | 616.80B |
| Daewon Pharmaceutical | 605.66B |
| Samjin Pharmaceuticals | 274.03B |
| Shinpoong Pharmaceutical Co.,Ltd | 233.80B |
| Bukwang Pharmaceutical | 200.68B |
| Korea United Pharm | 161.44B |
Dong-A ST News
- 1 year ago - Dong-A ST Secures European Approval for Stelara Biosimilar IMULDOSA - Financial Post
- 1 year ago - US FDA Approves Dong-A ST’s IMULDOSA™ (ustekinumab-srlf), a Biosimilar to STELARA® - Financial Post
- 1 year ago - US FDA Approves Dong-A ST's IMULDOSA™ (ustekinumab-srlf), a Biosimilar to STELARA® - Benzinga